To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
AmorChem invests in McGill ovarian cancer project
Canadian life sciences venture capital firm AmorChem has invested in a McGill University project focused on the identification of small molecules to treat an aggressive form of ovarian cancer.
